Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137972 | 0.78 | HTR7 (0.46) | ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL8072110 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL13872390 | 0.75 | KMT2A (0.43) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL6298933 | 0.73 | KMT2A (0.51) | ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL7312644 | 0.71 | MAPT (0.51) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL6298233 | 0.70 | NR4A2 (0.61) | ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL4099183 | 0.70 | TDP1 (0.49) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL4149623 | 0.69 | MAPT (0.44) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL29892846 | 0.69 | KMT2A (0.53) | ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL195311 | 0.69 | ALDH1A1 (0.62) | ALDH1A1KMT2AMAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2009-04-09 | — | — | US | disclosed |
| EP-1973916-A1 | PYRROLO Ýl,2-A¨QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | Faust Pharmaceuticals (FR) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007071379-A1 | PYRROLO [l,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2007-06-28 | — | — | WO | disclosed |
| EP-1798233-A1 | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof | Faust Pharmaceuticals (FR) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | ADORA3, ADORA2A, ADORA1 | ALDH1A1 1300/4885KMT2A 3312/4885MAPT 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.